Project Grant HT94252510873
Award Date 9/1/25
Completion Date 8/31/29
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15260, USA
Similar Awards
- This $1,264,474 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the University of Pittsburgh's research on "Molecular Insights into Immune Suppression in Kidney Cancer and Novel Therapeutic Opportunities". The grant, effective September 1, 2024 through August 31, 2028, will fund the university's investigations into improving understanding of immune system mechanisms involved in kidney cancer and...
- This $1,044,720 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to develop targeting kits using mono- and bi-paratopic antibody drug conjugates for chromophobe renal cell carcinoma. The award has an initial performance period from August 1, 2024 to July 31, 2027. The objective is to advance innovative therapeutic...
- This Project Grant award, valued at $1,124,896.00 and funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The research aims to characterize the role of aberrant FGD1 splicing in brain and bone metastasis in clear cell renal cell carcinoma. The award period runs from July 15, 2025 through July 14, 2029. The Military Medical...
- This $1,096,866 project grant was awarded on August 15, 2023 by the Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420). The grant, titled "TARGETING BRANCHED CHAIN AMINO ACIDS IN KIDNEY CANCER," will be carried out by The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, over a 3-year period ending on August 14, 2026. The funding supports biomedical...
- The Defense Health Agency awarded a $1,023,225 Project Grant under the Military Medical Research and Development program (CFDA# 12.420) to The Cleveland Clinic Foundation. The grant funds research to investigate the therapeutic relevance of targeting the anti-apoptotic Bcl-xL protein in kidney cancer. A sub-award to Harvard T.H. Chan School of Public Health will perform BH3 profiling to compare apoptotic responses in renal cell carcinomas under varied conditions, including treatment with BH3...
- The Defense Health Agency awarded a $464,261 project grant to The Royal Institution For The Advancement Of Learning, a private, non-profit educational institution in Montreal, Canada, to develop the next generation of prognostic tools for localized clear cell renal cell carcinoma. The grant, awarded under the Military Medical Research and Development (CFDA 12.420) program, will fund research to integrate genomic, clinical, and pathological features to create advanced prognostic tools for this...
- The Project Grant award of $1,387,727.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma" research project conducted by the Sloan-Kettering Institute for Cancer Research in New York, NY. The award period runs from September 1, 2025 to August 31, 2029. The research aims to advance the scientific understanding and develop innovative diagnostic...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research on the role of fatty acid metabolism in chromophobe renal cell carcinoma. The $172,374 award was made on August 1, 2025, with an ultimate completion date of September 29, 2026. The principal recipient is Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, a prominent academic medical center and research institution in...
- This $769,073 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to define and target cancer cell-intrinsic vulnerabilities in renal cell carcinoma. The grant was awarded to the Royal Institution for the Advancement of Learning / McGill Office of Sponsored Research Division, a private university affiliated with McGill University in Montreal, Canada. The research will be conducted from August 1, 2024...
- The Department of the Army Medical Command awarded Duke University a $1,932,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of September 1, 2022 through August 31, 2025. The grant funds research to define cellular and genetic factors for renal cell carcinoma subtypes. Through this award, Duke University researchers will investigate medical solutions for kidney cancer on the cellular and genetic levels to advance understanding,...